ACORQ vs. SCNI, ACOR, TCBP, SQZ, WINT, ELOX, GMDAQ, GMDA, ALBT, and AKAN
Should you be buying Acorda Therapeutics stock or one of its competitors? The main competitors of Acorda Therapeutics include Scinai Immunotherapeutics (SCNI), Acorda Therapeutics (ACOR), TC Biopharm (TCBP), SQZ Biotechnologies (SQZ), Windtree Therapeutics (WINT), Eloxx Pharmaceuticals (ELOX), Gamida Cell (GMDAQ), Gamida Cell (GMDA), Avalon GloboCare (ALBT), and Akanda (AKAN). These companies are all part of the "medical" sector.
Scinai Immunotherapeutics (NASDAQ:SCNI) and Acorda Therapeutics (NASDAQ:ACORQ) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends, media sentiment, valuation and community ranking.
In the previous week, Acorda Therapeutics' average media sentiment score of 0.00 equaled Scinai Immunotherapeutics'average media sentiment score.
58.4% of Scinai Immunotherapeutics shares are held by institutional investors. Comparatively, 12.7% of Acorda Therapeutics shares are held by institutional investors. 60.9% of Scinai Immunotherapeutics shares are held by company insiders. Comparatively, 2.6% of Acorda Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Scinai Immunotherapeutics has higher earnings, but lower revenue than Acorda Therapeutics. Scinai Immunotherapeutics is trading at a lower price-to-earnings ratio than Acorda Therapeutics, indicating that it is currently the more affordable of the two stocks.
Scinai Immunotherapeutics has a beta of 2.45, suggesting that its share price is 145% more volatile than the S&P 500. Comparatively, Acorda Therapeutics has a beta of 1.71, suggesting that its share price is 71% more volatile than the S&P 500.
Scinai Immunotherapeutics and Acorda Therapeutics both received 0 outperform votes by MarketBeat users.
Scinai Immunotherapeutics has a net margin of 0.00% compared to Scinai Immunotherapeutics' net margin of -214.95%. Acorda Therapeutics' return on equity of 0.00% beat Scinai Immunotherapeutics' return on equity.
Summary
Scinai Immunotherapeutics beats Acorda Therapeutics on 8 of the 10 factors compared between the two stocks.
Get Acorda Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACORQ and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ACORQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ACORQ vs. The Competition
Acorda Therapeutics Competitors List
Related Companies and Tools
